-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Observations on patents and other IP from a dual-licensed practitioner
As discussed in earlier posts, back in early 2001 The Medicines Company (TMC) missed by one day the deadline to request a patent term extension (PTE) for US 5,196,404, which…
In an earlier post, I discussed The Medicines Company’s last-ditch effort to save the exclusivity for its Angiomax product via its US 5,196,404, which was due to expire on March…
As noted here and elsewhere, The Medicines Company (TMC) failed to secure a patent term extension (PTE) for US 5,196,404, its patent on bivalirudin, a peptide drug that is…
(revised September 6, 2009) The Medicines Company (TMC) has a problem. US 5,196,404, the patent that covers its product bivalirudin (sold in the USA under the name Angiomax®), will…
Israel has both pre-grant patent oppositions as well as post-grant revocation proceedings. Sometimes the PTO’s decisions in these proceedings make sense. Sometimes they don’t. A recent opposition decision, Unipharm v…
I’m Dan Feigelson. I’ve been practicing patent law for over 30 years. I’m also opinionated, as you may discover in reading my writings here.
America-Israel Patent Law Blog 